Cargando…
Evaluation of a Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union
Bioequivalence (BE) of products containing narrow therapeutic index (NTI) drugs in the European Union is currently established by demonstrating that the 90% confidence interval for the ratio of the population geometric means of the test compared to the reference product’s AUC, and in certain cases C...
Autores principales: | Paixão, Paulo, Silva, Nuno, Guerreiro, Rita Bento, Blake, Kevin, Bonelli, Milton, Morais, José Augusto Guimarães, García-Arieta, Alfredo, Gouveia, Luís Filipe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697618/ https://www.ncbi.nlm.nih.gov/pubmed/36365166 http://dx.doi.org/10.3390/pharmaceutics14112349 |
Ejemplares similares
-
Predictive Potential of C(max) Bioequivalence in Pilot Bioavailability/Bioequivalence Studies, through the Alternative ƒ(2) Similarity Factor Method
por: Henriques, Sara Carolina, et al.
Publicado: (2023) -
Promoting Safe Early Clinical Research of Novel Drug Candidates: A European Union Regulatory Perspective
por: Ponzano, Stefano, et al.
Publicado: (2017) -
Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients
por: González-Álvarez, Isabel, et al.
Publicado: (2022) -
Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products
por: Ruiz-Picazo, Alejandro, et al.
Publicado: (2019) -
Alternative Analysis Approaches for the Assessment of Pilot Bioavailability/Bioequivalence Studies
por: Henriques, Sara Carolina, et al.
Publicado: (2023)